FibroGen Stock Forecast, Price & News

FibroGen's stock was trading at $35.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FGEN stock has increased by 21.5% and is now trading at $43.01.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for FibroGen.

FibroGen is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020.
View our earnings forecast for FibroGen.

FibroGen Inc (NASDAQ:FGEN) posted its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.64) by $0.31. The biopharmaceutical company earned $42.90 million during the quarter, compared to analyst estimates of $48.29 million. FibroGen had a negative return on equity of 60.97% and a negative net margin of 287.01%. The company's revenue for the quarter was down 77.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.26 earnings per share.
View FibroGen's earnings history.

5 Wall Street analysts have issued 1-year price targets for FibroGen's shares. Their forecasts range from $40.00 to $90.00. On average, they expect FibroGen's stock price to reach $59.60 in the next twelve months. This suggests a possible upside of 38.6% from the stock's current price.
View analysts' price targets for FibroGen.

FibroGen saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 6,910,000 shares, an increase of 16.1% from the August 31st total of 5,950,000 shares. Based on an average trading volume of 657,000 shares, the days-to-cover ratio is currently 10.5 days. Approximately 8.4% of the company's stock are sold short.
View FibroGen's Short Interest.

Some companies that are related to FibroGen include Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), Catalent (CTLT), GRIFOLS S A/S (GRFS), Dr.Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Elanco Animal Health (ELAN), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), CureVac B.V. (CVAC), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), Mylan (MYL), Mirati Therapeutics (MRTX) and Myokardia (MYOK).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

FibroGen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.35%), FMR LLC (7.10%), First Trust Advisors LP (1.89%), Bank of New York Mellon Corp (1.67%), Goldman Sachs Group Inc. (1.21%) and Charles Schwab Investment Management Inc. (0.88%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, Enrique A Conterno, James A Schoeneck, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Thomas B Neff and Thomas F Kearns Jr.
View institutional ownership trends for FibroGen.

FGEN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Artal Group S.A., Rhenman & Partners Asset Management AB, UBS Group AG, Prudential Financial Inc., Barclays PLC, Nuveen Asset Management LLC, and Alps Advisors Inc.. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, and Thomas F Kearns Jr.
View insider buying and selling activity for FibroGen.

FGEN stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Bank of New York Mellon Corp, First Trust Advisors LP, Sei Investments Co., Principal Financial Group Inc., Principal Financial Group Inc., Man Group plc, and Hudson Bay Capital Management LP.
View insider buying and selling activity for FibroGen.

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FGEN stock can currently be purchased for approximately $43.01.

FibroGen has a market capitalization of $3.89 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. FibroGen employs 461 workers across the globe.

The official website for FibroGen is www.fibrogen.com.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]